Two different 18F-FDG brain PET metabolic patterns in autoimmune limbic encephalitis

Clinical Nuclear Medicine

Volumn 37, Issue 9, 2012, Pages

  Fisher, Ronald E ^a   Patel, Niraj R ^a   Lai, Eugene C ^b   Schulz, Paul E ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

18F fluorodeoxyglucose (FDG); autoimmune; brain; encephalitis; positron emission tomography (PET)

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IMMUNOSUPPRESSIVE AGENT; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; AUTOIMMUNE LIMBIC ENCEPHALITIS; BRAIN METABOLISM; BRAIN SCINTISCANNING; CEREBROSPINAL FLUID; CLINICAL ARTICLE; FEMALE; HUMAN; HYPERMETABOLISM; IMMUNOSUPPRESSIVE TREATMENT; MALE; MEDICAL RECORD REVIEW; ORBITAL CORTEX; PARANEOPLASTIC NEUROPATHY; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; TEMPORAL CORTEX; AUTOIMMUNE DISEASE; BRAIN; FOLLOW UP; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PROGNOSIS; SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; AUTOIMMUNE DISEASES; BRAIN; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; LIMBIC ENCEPHALITIS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; YOUNG ADULT;

EID: 84865587794     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31824852c7     Document Type: Article

References (37)

1. Brierley JB, Corsellis CA, Hierons R, et al. Subacute encephalitis of later adult life mainly affecting the limbic areas. Brain. 1960;83:357-370.
2. Wandinger KP, Saschenbrecker S, Stoecker W, et al. Anti-NMDA-receptor encephalitis: a severe, multistage, treatable disorder presenting with psychosis. J Neuroimmunol. 2011;231:86-91.
3. Lancaster E, Lai M, Peng X, et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol. 2010;9:67-76.
4. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7:1091-1098.
5. Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10:63-74.
6. Wong SH, Saunders MD, Larner AJ, et al. An effective immunotherapy regimen for VGKC antibody-positive limbic encephalitis. J Neurol Neurosurg Psychiatry. 2010;81:1167-1169.
7. Mori M, Kuwabara S, Yoshiyama M, et al. Successful immune treatment for non-paraneoplastic limbic encephalitis. J Neurol Sci. 2002;201:85-88. (Pubitemid 34876910)
8. Vincent A, Buckley C, Schott JM, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain. 2004;127:701-712. (Pubitemid 38295483)
9. Lai M, Hughes EG, Peng X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol. 2009;65:424-434.
10. Malter MP, Helmstaedter C, Urbach H, et al. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol. 2010;67: 470-478.
11. Schott JM, Harkness K, Barnes J, et al. Amnesia, cerebral atrophy, and autoimmunity. Lancet. 2003;361:1266. (Pubitemid 36428581)
12. Lai M, Huijbers MG, Lancaster E, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol. 2010;9:776-785.
13. Bataller L, Kleopa KA, Wu GF, et al. Autoimmune limbic encephalitis in 39 patients: immunophenotypes and outcomes. J Neurol Neurosurg Psychiatry. 2007;78:381-385. (Pubitemid 46580546)
14. Sokoloff L. Modeling metabolic processes in the brain in vivo. Ann Neurol. 1984;15(suppl):S1-S11. (Pubitemid 14138653)
15. Silverman DH. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med. 2004;45:594-607. (Pubitemid 47618590)
16. Henkel K, Zerr I, Hertel A, et al. Positron emission tomography with E(18)F^FDG in the diagnosis of Creutzfeldt-Jakob disease (CJD). J Neurol. 2002;249:699-705. (Pubitemid 34651751)
17. Mohr BC, Minoshima S. 18F fluorodeoxyglucose PET/CT findings in a case of anti-NMDA receptor encephalitis. Clin Nucl Med. 2010;35:461-463.
18. Pillai SC, Gill D, Webster R, et al. Cortical hypometabolism demonstrated by PET in relapsing NMDA receptor encephalitis. Pediatr Neurol. 2010;43: 217-220.
19. Basu S, Alavi A. Role of FDG-PET in the clinical management of paraneoplastic neurological syndrome: detection of the underlying malignancy and the brain PET-MRI correlates. Mol Imaging Biol. 2008;10:131-137.
20. Provenzale JM, Barboriak DP, Coleman RE. Limbic encephalitis: comparison of FDG PET and MR imaging findings. Am J Roentgenol. 1998;170: 1659-1660. (Pubitemid 28237669)
21. Fakhoury T, Abou-Khalil B, Kessler RM. Limbic encephalitis and hyperactive foci on PET scan. Seizure. 1999;8:427-431.
22. Kassubek J, Juengling FD, Nitzsche EU, et al. Limbic encephalitis investigated by 18FDG-PET and 3D MRI. J Neuroimaging. 2001;11:55-59. (Pubitemid 32194927)
23. Fauser S, Talazko J, Wagner K, et al. FDG-PET and MRI in potassium channel antibody-associated non-paraneoplastic limbic encephalitis: correlation with clinical course and neuropsychology. Acta Neurol Scand. 2005; 111:338-343. (Pubitemid 40559411)
24. Ances BM, Vitaliani R, Taylor RA, et al. Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain. 2005;128:1764-1777. (Pubitemid 41373648)
25. Gast H, Schindler K, Z'Graggen WJ, et al. Improvement of non-paraneoplastic voltage-gated potassium channel antibody-associated limbic encephalitis without immunosuppressive therapy. Epilepsy Behav. 2010;17:555-557.
26. Maeder-Ingvar M, Prior JO, Irani SR, et al. FDG-PET hyperactivity in basal ganglia correlating with clinical course in anti-NDMA-R antibodies encephalitis. J Neurol Neurosurg Psychiatry. 2011;82:235-236.
27. Fulham MJ, Brunetti A, Aloj L, et al. Decreased cerebral glucose metabolism in patients with brain tumors: an effect of corticosteroids. J Neurosurg. 1995;83:657-664.
28. Irani SR, Bera K, Waters P, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain. 2010;133: 1655-1667.
29. Dadparvar S, Anderson GS, Bhargava P, et al. Paraneoplastic encephalitis associated with cystic teratoma is detected by fluorodeoxyglucose positron emission tomography with negative magnetic resonance image findings. Clin Nucl Med. 2003;28:893-896. (Pubitemid 38281847)
30. Iizuka T, Sakai F, Ide T, et al. Anti-NMDA receptor encephalitis in Japan: longterm outcome without tumor removal. Neurology. 2008;70:504-511. (Pubitemid 351653374)
31. Maqbool M, Oleske DA, Huq AH, et al. Novel FDG-PET findings in anti-NMDA receptor encephalitis: a case based report. J Child Neurol. 2011;26: 1325-1328.
32. Hughes EG, Peng X, Gleichman AJ, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci. 2010;30:5866-5875.
33. Moscato EH, Jain A, Peng X, et al. Mechanisms underlying autoimmune synaptic encephalitis leading to disorders of memory, behavior and cognition: insights from molecular, cellular and synaptic studies. Eur J Neurosci. 2010; 32:298-309.
34. Barrington SF,Koutroumanidis M, Agathonikou A, et al. Clinical value of "ictal" FDG-positron emission tomography and the routine use of simultaneous scalp EEG studies in patients with intractable partial epilepsies. Epilepsia. 1998; 39:753-766. (Pubitemid 28319513)
35. Dong C, Sriram S, Delbeke D, et al. Aphasic or amnesic status epilepticus detected on PET but not EEG. Epilepsia. 2009;50:251-255.
36. Handforth A, Cheng JT, Mandelkern MA, et al. Markedly increased mesiotemporal lobe metabolism in a case with PLEDs: further evidence that PLEDs are a manifestation of partial status epilepticus. Epilepsia. 1994;35:876-881. (Pubitemid 24278046)
37. Engel J Jr, Kuhl DE, Phelps ME. Patterns of human local cerebral glucose metabolism during epileptic seizures. Science. 1982;218:64-66. (Pubitemid 12024620)